A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe

Janan Janine Dietrich, Nadia Ahmed, Emily L Webb, Gugulethu Tshabalala, Stefanie Hornschuh, Mamakiri Mulaudzi, Millicent Atujuna, Lynda Stranix-Chibanda, Teacler Nematadzira, Andrew Sentoogo Ssemata, Richard Muhumuza, Janet Seeley, Linda-Gail Bekker, Helen A Weiss, Neil Martinson, Julie Fox, CHAPS team, Janan Janine Dietrich, Nadia Ahmed, Emily L Webb, Gugulethu Tshabalala, Stefanie Hornschuh, Mamakiri Mulaudzi, Millicent Atujuna, Lynda Stranix-Chibanda, Teacler Nematadzira, Andrew Sentoogo Ssemata, Richard Muhumuza, Janet Seeley, Linda-Gail Bekker, Helen A Weiss, Neil Martinson, Julie Fox, CHAPS team

Abstract

Introduction: Sub-Saharan Africa (SSA) carries the burden of the HIV epidemic, especially among adolescents and young people (AYP). Little is known about pre-exposure prophylaxis (PrEP) uptake and preferences among AYP in SSA. We describe preferences for daily and on-demand PrEP among AYP in South Africa, Uganda and Zimbabwe.

Methods: A cross-sectional survey was conducted in 2019 among 13- to 24-year olds, capturing socio-demographics, HIV risk behaviours and preferences for daily or on-demand PrEP. Logistic regression models were used to estimate odds ratios, adjusting for site, sex and age.

Results and discussion: A total of 1330 participants from Cape Town (n = 239), Johannesburg (n = 200), Entebbe (n = 491) and Chitungwiza (n = 400) were enrolled; 673 (51%) were male, and the median age was 19 years (interquartile range 17-22 years). Of 1287 participants expressing a preference, 60% indicated a preference for on-demand PrEP with differences by site (p < 0.001), sex (p < 0.001) and age group (p = 0.003). On-demand PrEP was most preferred in Entebbe (75%), among males (65%) versus females (54%) and in older participants (62% in 18- to 24-year-olds vs. 47% in 13- to 15-year-olds). After adjusting for site, sex and age group, preference for on-demand PrEP decreased as sex frequency over the past month increased (p-trend = 0.004) and varied with the number of partners in the last 6 months, being least popular among those reporting four or more partners (p = 0.02). Participants knowing further in advance that they were likely to have sex were more likely to prefer on-demand PrEP (p-trend = 0.02). Participants having a larger age gap with their most recent partner and participants whose last partner was a transactional sex partner or client were both less likely to prefer on-demand compared to daily PrEP (p = 0.05 and p = 0.09, respectively). Participants who knew their most recent partner was living with HIV or who did not know the HIV status of their most recent partner were less likely to prefer on-demand PrEP (p = 0.05).

Conclusions: Our data show that AYP in four SSA communities prefer on-demand over daily PrEP options, with differences seen by site, age and sex. PrEP demand creation needs to be reviewed, optimized and tailored to socio-demographic differences and designed in conjunction with AYP.

Keywords: Africa; HIV; on-demand; oral pre-exposure prophylaxis; young people.

Conflict of interest statement

The authors declare no competing interests.

© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

References

    1. UNAIDS . UNAIDS Data 2020. Geneva, Switzerland: UNAIDS; 2020.
    1. UNAIDS . Global HIV and AIDS Statistics ‐ Factsheet. Geneva, Switzerland: UNAIDS; 2021.
    1. UNAIDS . Report on the Global HIV/AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2000.
    1. Kharsany ABM, Karim QA. HIV infection and AIDS in sub‐Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10:34–8.
    1. Allen E, Gordon A, Krakower D, Hsu K. HIV preexposure prophylaxis for adolescents and young adults. Curr Opin Pediatr. 2017;29(4):399–406.
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre‐exposure prophylaxis to prevent the acquisition of HIV‐1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open‐label randomised trial. Lancet. 2016;387(10013):53–60.
    1. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On‐demand preexposure prophylaxis in men at high risk for HIV‐1 infection. N Engl J Med. 2015;373(23):2237–46.
    1. PrEP Watch . Global PrEP Tracker. 2021. [cited 2021 May 10]. Available at:
    1. WHO . Global data shows increasing PrEP use and widespread adoption of WHO PrEP recommendations. 2021. [cited 2021 May 17] Available at:
    1. SANAC . Monitoring and evaluation plan for the national strategic plan on HIV, TB and STI (2017–2022). Pretoria, South Africa: SANAC; 2017.
    1. Ministry of Health Uganda . Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Kampala, Uganda: Government of Uganda; 2018.
    1. Ministry of Health and Child Care, The National Medicine and Therapeutics Policy Advisory Committee, The AIDS and TB Directorate, Ministry of Health and Child Care . Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe. Harare, Zimbabwe: The National Medicine and Therapeutics Policy Advisory Committee and the AIDS and TB Directorate, Ministry of Health and Child Care; 2016.
    1. Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre‐exposure prophylaxis in South African adolescents: an open‐label single‐arm phase 2 trial. Lancet Child Adolesc Health. 2020;4(12):875–83.
    1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.
    1. Abdulrahman SA, Rampal L, Ibrahim F, Radhakrishnan AP, Shahar HK, Othman N, et al. Mobile phone reminders and peer counseling improve adherence and treatment outcomes of patients on ART in Malaysia: a randomized clinical trial. PLoS One. 2017;12(5):e0177698.
    1. Swendeman D, Arnold EM, Harris D, Fournier J, Comulada WS, Reback C, et al. Text‐messaging, online peer support group, and coaching strategies to optimize the HIV prevention continuum for youth: protocol for a randomized controlled trial. JMIR Res Protoc. 2019;8(8):e11165.
    1. Nash S, Dietrich J, Ssemata AS, Herrera C, O'Hagan K, Else L, et al. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre‐exposure prophylaxis regimens for adolescents in sub‐Saharan Africa‐study protocol for a mixed‐methods study including a randomised controlled trial. Trials. 2020;21(1):900.
    1. Govender K, Masebo WGB, Nyamaruze P, Cowden RG, Schunter BT, Bains A. HIV prevention in adolescents and young people in the eastern and southern African region: a review of key challenges impeding actions for an effective response. Open AIDS J. 2018;12:53–67.
    1. Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on‐demand pre‐exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.
    1. Eakle R, Weatherburn P, Bourne A. Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale‐up: a synthesis of evidence from sub‐Saharan Africa. J Int AIDS Soc. 2019;22(4):e25306.
    1. Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre‐exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at‐risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.
    1. Dietrich JJ, Atujuna M, Tshabalala G, Hornschuh S, Mulaudzi M, Koh M, et al. A qualitative study to identify critical attributes and attribute‐levels for a discrete choice experiment on oral pre‐exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa. BMC Health Serv Res. 2021;21(1):17.
    1. CDC . On‐demand PrEP — if I am not at ongoing risk for getting HIV, can I take PrEP only when I'm at risk? 2022. [cited 2022 June 28]. Available at:
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir‐based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
    1. Smelser NJ, Baltes PB. International encyclopedia of the social & behavioral sciences. Amsterdam: Elsevier; 2001.
    1. Pernegger L, Godehart S. Townships in the South African geographic landscape–physical and social legacies and challenges. Training for Township Renewal Initiative. South Africa. 2007.
    1. ODK . Collect data anywhere. 2020. [cited 2021 May 17]. Available at:
    1. Stata Corp . Stata release 15. 2021. [cited 2021 May 17]. Available at:
    1. Macapagal K, Nery‐Hurwit M, Matson M, Crosby S, Greene GJ. Perspectives on and preferences for on‐demand and long‐acting PrEP among sexual and gender minority adolescents assigned male at birth. Sex Res Social Policy. 2021;18(1):39–53.
    1. Molina JM, Beniguel L, Rojas‐Castro D, Ghosn J, Algarte‐Genin M, Pialoux G, et al. Incidence of HIV‐infection in the ANRS Prévenir study in Paris region with daily or on‐demand PrEP with TDF/FTC. 22nd International AIDS Conference (AIDS 2018); 23–27 July 2018; Amsterdam, the Netherlands: International AIDS Society.
    1. Molina JM, Pialoux G, Ohayon M, Cotte L, Valin L, Ghosn J, et al. One‐year experience with pre‐exposure prophylaxis (PrEP) implementation in France with TDF/FTC. 9th International AIDS Conference (AIDS 2017); 23–26 July 2017; Paris, France: International AIDS Society.
    1. Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K, et al. Choosing between daily and event‐driven pre‐exposure prophylaxis: results of a Belgian PrEP Demonstration Project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.
    1. Hoornenborg E, Achterbergh RC, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, et al. Men who have sex with men more often chose daily than event‐driven use of pre‐exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105.
    1. Zimmermann HML, Jongen VW, Boyd A, Hoornenborg E, Prins M, de Vries HJC, et al. Decision‐making regarding condom use among daily and event‐driven users of preexposure prophylaxis in the Netherlands. AIDS. 2020;34(15):2295–304.
    1. Shao Y, Williamson C. The HIV‐1 epidemic: low‐ to middle‐income countries. Cold Spring Harb Perspect Med. 2012;2(3):a007187.
    1. Adam PC, de Wit JB, Toskin I, Mathers BM, Nashkhoev M, Zablotska I, et al. Estimating levels of HIV testing, HIV prevention coverage, HIV knowledge, and condom use among men who have sex with men (MSM) in low‐income and middle‐income countries. J Acquir Immune Defic Syndr. 2009;52(Suppl 2):S143–51.
    1. Thapa S, Hannes K, Cargo M, Buve A, Peters S, Dauphin S, et al. Stigma reduction in relation to HIV test uptake in low‐ and middle‐income countries: a realist review. BMC Public Health. 2018;18(1):1277.
    1. Han J, Bouey JZ, Wang L, Mi G, Chen Z, He Y, et al. PrEP uptake preferences among men who have sex with men in China: results from a National Internet Survey. J Int AIDS Soc. 2019;22(2):e25242.
    1. Yi S, Tuot S, Mwai GW, Ngin C, Chhim K, Pal K, et al. Awareness and willingness to use HIV pre‐exposure prophylaxis among men who have sex with men in low‐ and middle‐income countries: a systematic review and meta‐analysis. J Int AIDS Soc. 2017;20(1):21580.
    1. Cornelisse VJ, Lal L, Price B, Ryan KE, Bell C, Owen L, et al. Interest in switching to on‐demand HIV pre‐exposure prophylaxis (PrEP) among Australian users of daily PrEP: an online survey. Open Forum Infect Dis. 2019;6(7):ofz287.
    1. Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, et al. Daily or on‐demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre‐exposure prophylaxis: experience from a hospital‐based clinic in France. AIDS. 2018;32(15):2161–9.
    1. Stack C, Oldenburg C, Mimiaga M, Elsesser SA, Krakower D, Novak DS, et al. Sexual behavior patterns and PrEP dosing preferences in a large sample of North American men who have sex with men. J Acquir Immune Defic Syndr. 2016;71(1):94–101.
    1. Beymer MR, Gildner JL, Holloway IW, Landovitz RJ. Acceptability of injectable and on‐demand pre‐exposure prophylaxis among an online sample of young men who have sex with men in California. LGBT Health. 2018;5(6):341–9.
    1. Greenwald ZR, Maheu‐Giroux M, Szabo J, Robin JAB, Boissonnault M, Nguyen V‐K, et al. Cohort profile: l'Actuel Pre‐Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada. BMJ Open. 2019;9(6):e028768.
    1. Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, et al. Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. AIDS Care. 2020;32(2):249–54.
    1. Beauclair R, Helleringer S, Hens N, Delva W. Age differences between sexual partners, behavioural and demographic correlates, and HIV infection on Likoma Island, Malawi. Sci Rep. 2016;6(1):36121.
    1. Maughan‐Brown B, Kenyon C, Lurie MN. Partner age differences and concurrency in South Africa: implications for HIV‐infection risk among young women. AIDS Behav. 2014;18(12):2469–76.
    1. Harling G, Newell ML, Tanser F, Bärnighausen T. Partner age‐disparity and HIV incidence risk for older women in rural South Africa. AIDS Behav. 2015;19(7):1317–26.
    1. Harling G, Newell ML, Tanser F, Kawachi I, Subramanian SV, Bärnighausen T. Do age–disparate relationships drive HIV incidence in young women? Evidence from a population cohort in rural KwaZulu‐Natal, South Africa. J Acquir Immune Defic Syndr. 2014;66(4):443–51.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren